Terms: = Prostate cancer AND MAX, MGC36767, 4149, ENSG00000125952, MGC18164, MGC10775, P61244, MGC11225, orf1, MGC34679 AND Prognosis
18 results:
1. PSMA PET/MR is a New Imaging Option for Identifying Glioma Recurrence and Predicting prognosis.
Xiong M; Chen Z; Zhou C; Yang X; Hu W; Jiang Y; Zheng R; Fan W; Mou Y; Lin X
Recent Pat Anticancer Drug Discov; 2024; 19(3):383-395. PubMed ID: 38214322
[TBL] [Abstract] [Full Text] [Related]
2. 68 Ga-PSMA-11 PET/CT Imaging in Brain Gliomas and Its Correlation With Clinicopathological Prognostic Parameters.
Verma P; Singh BK; Sudhan MD; Singh RK; Bagul SD; Chandak AR; Soni BK; Shelly D; Basu S
Clin Nucl Med; 2023 Dec; 48(12):e559-e563. PubMed ID: 37883060
[TBL] [Abstract] [Full Text] [Related]
3. Multi-candidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionation.
Wilkins A; Gusterson B; Tovey H; Griffin C; Stuttle C; Daley F; Corbishley CM; Dearnaley D; Hall E; Somaiah N
EBioMedicine; 2023 Feb; 88():104436. PubMed ID: 36708693
[TBL] [Abstract] [Full Text] [Related]
4. The Prognostic Value of Posttreatment
Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L
J Nucl Med; 2023 Jan; 64(1):69-74. PubMed ID: 35738906
[No Abstract] [Full Text] [Related]
5. Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine prostate cancer.
Ton AT; Foo J; Singh K; Lee J; Kalyta A; Morin H; Perez C; Ban F; Leblanc E; Lallous N; Cherkasov A
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269731
[TBL] [Abstract] [Full Text] [Related]
6. Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on prostate-Specific Membrane Antigen-Targeted
Zukotynski KA; Emmenegger U; Hotte S; Kapoor A; Fu W; Blackford AL; Valliant J; Bénard F; Kim CK; Markowski MC; Eisenberger MA; Antonarakis ES; Pienta KJ; Gorin MA; Lubanovic M; Kim J; Pomper MG; Cho SY; Rowe SP
J Nucl Med; 2021 Oct; 62(10):1430-1437. PubMed ID: 33608426
[TBL] [Abstract] [Full Text] [Related]
7. Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of
Zou Q; Jiao J; Zou MH; Li MZ; Yang T; Xu L; Zhang Y
Abdom Radiol (NY); 2020 Dec; 45(12):4202-4213. PubMed ID: 32948911
[TBL] [Abstract] [Full Text] [Related]
8. Going deeper through the Gleason scoring scale: An automatic end-to-end system for histology prostate grading and cribriform pattern detection.
Silva-Rodríguez J; Colomer A; Sales MA; Molina R; Naranjo V
Comput Methods Programs Biomed; 2020 Oct; 195():105637. PubMed ID: 32653747
[TBL] [Abstract] [Full Text] [Related]
9. Impact of Anatomic Location of Bone Metastases on prognosis in Metastatic Castration-Resistant prostate cancer.
Roth AR; Harmon SA; Perk TG; Eickhoff J; Choyke PL; Kurdziel KA; Dahut WL; Apolo AB; Morris MJ; Perlman SB; Liu G; Jeraj R
Clin Genitourin Cancer; 2019 Aug; 17(4):306-314. PubMed ID: 31221545
[TBL] [Abstract] [Full Text] [Related]
10. Correlation of Prognostic Gleason Grade Grouping and Histopathological Parameters: Can the "New System" Reflect the Pathological Perspective for prognosis?
Dere Y; Altınboğa AA; Yaldır E; Bal K; Tosun K; Sarı A
Arch Iran Med; 2018 Nov; 21(11):518-523. PubMed ID: 30551692
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic value of 68 Ga PSMA I&T PET/CT SUV parameters on survival outcome in advanced prostat cancer.
Komek H; Can C; Yilmaz U; Altindag S
Ann Nucl Med; 2018 Oct; 32(8):542-552. PubMed ID: 30006752
[TBL] [Abstract] [Full Text] [Related]
12. Reproducibility and Repeatability of Semiquantitative
Vargas HA; Kramer GM; Scott AM; Weickhardt A; Meier AA; Parada N; Beattie BJ; Humm JL; Staton KD; Zanzonico PB; Lyashchenko SK; Lewis JS; Yaqub M; Sosa RE; van den Eertwegh AJ; Davis ID; Ackermann U; Pathmaraj K; Schuit RC; Windhorst AD; Chua S; Weber WA; Larson SM; Scher HI; Lammertsma AA; Hoekstra OS; Morris MJ
J Nucl Med; 2018 Oct; 59(10):1516-1523. PubMed ID: 29626121
[No Abstract] [Full Text] [Related]
13. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer.
Hormaechea-Agulla D; Jiménez-Vacas JM; Gómez-Gómez E; L-López F; Carrasco-Valiente J; Valero-Rosa J; Moreno MM; Sánchez-Sánchez R; Ortega-Salas R; Gracia-Navarro F; Culler MD; Ibáñez-Costa A; Gahete MD; Requena MJ; Castaño JP; Luque RM
FASEB J; 2017 Nov; 31(11):4682-4696. PubMed ID: 28705809
[TBL] [Abstract] [Full Text] [Related]
14. Baseline and follow-up association of the max-PC in Men with newly diagnosed prostate cancer.
Tavlarides AM; Ames SC; Thiel DD; Diehl NN; Parker AS
Psychooncology; 2015 Apr; 24(4):451-7. PubMed ID: 24953309
[TBL] [Abstract] [Full Text] [Related]
15. Potential upstream regulators of cannabinoid receptor 1 signaling in prostate cancer: a Bayesian network analysis of data from a tissue microarray.
Häggström J; Cipriano M; Forshell LP; Persson E; Hammarsten P; Stella N; Fowler CJ
Prostate; 2014 Aug; 74(11):1107-17. PubMed ID: 24913716
[TBL] [Abstract] [Full Text] [Related]
16. prognosis Related to Metastatic Burden Measured by ¹⁸F-Fluorocholine PET/CT in Castration-Resistant prostate cancer.
Kwee SA; Lim J; Watanabe A; Kromer-Baker K; Coel MN
J Nucl Med; 2014 Jun; 55(6):905-10. PubMed ID: 24676753
[TBL] [Abstract] [Full Text] [Related]
17. Clinical significance of a large difference (≥ 2 points) between biopsy and post-prostatectomy pathological Gleason scores in patients with prostate cancer.
Yoo C; Oh CY; Cho JS; Song C; Seo SI; Ahn H; Hwang TK; Cheon J; Lee KH; Kwon TG; Jung TY; Chung MK; Lee SE; Lee HM; Lee ES; Choi YD; Chung BH; Kim HJ; Kim WJ; Byun SS; Choi HY
J Korean Med Sci; 2011 Apr; 26(4):507-12. PubMed ID: 21468257
[TBL] [Abstract] [Full Text] [Related]
18. Assessment of the effect of haematocrit-dependent arterial input functions on the accuracy of pharmacokinetic parameters in dynamic contrast-enhanced MRI.
Just N; Koh DM; D'Arcy J; Collins DJ; Leach MO
NMR Biomed; 2011 Aug; 24(7):902-15. PubMed ID: 21290457
[TBL] [Abstract] [Full Text] [Related]
